Navigation Links
Telik Announces Publication of Positive Phase 1-2a Results of a Multicenter Study of TELCYTA(R) in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer
Date:10/1/2009

PALO ALTO, Calif., Oct. 1 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) today announced the publication of the positive results from a Phase 1-2a multicenter, dose-ranging study of TELCYTA in combination with carboplatin and paclitaxel as first-line therapy for patients with nonsmall cell lung cancer (NSCLC) in a leading peer reviewed publication, the Journal of Thoracic Oncology, October 2009; Vol. 4, No. 10. Data on this study were presented at the 98th annual meeting of the American Association for Cancer Research (AACR) on April 17, 2007.

One hundred twenty-nine patients were treated with TELCYTA in combination with carboplatin and paclitaxel, of whom 100 were continuing to respond at the end of combination therapy and eligible to receive single agent TELCYTA maintenance therapy. Those patients who received the TELCYTA combination therapy followed by TELCYTA maintenance therapy vs. no maintenance therapy had a median progression-free survival (PFS) of 6.8 months vs. 3.9 months, respectively (p< 0.0001). The difference in PFS correlated with a median survival of 16.8 months in the maintenance group vs. 8.8 months for those without maintenance therapy (p<0.0001). TELCYTA in combination with carboplatin and paclitaxel chemotherapy followed by TELCYTA maintenance therapy was well tolerated. TELCYTA may be suited to application as maintenance therapy, an area of current intense interest for the treatment of lung cancer patients. In addition, the regimen appeared active across all types of NSCLC and ongoing investigations are attempting to identify the characteristics of the NSCLC population most likely to benefit from this approach.

About Telik

Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to trea
'/>"/>

SOURCE Telik, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Telik Announces Presentation of Preclinical Data on Dual Inhibitors of Aurora Kinases and VEGFR2
2. Telik Announces Preclinical Data Demonstrating Anti-Cancer Activity of Dual Inhibitors of Aurora Kinase and VEGFR2
3. Telik Announces Telintra Presentation at American Society of Hematology Annual Meeting
4. Telik Announces Initiation of Two Phase 2 Randomized TELINTRA Studies
5. Teliks Proteasome Inhibitor Program Meets a Preclinical Development Milestone
6. Telik Announces Presentation at ASCO Annual Meeting
7. Telik Announces Publication of Positive Phase 1 Results of a Multicenter Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets In Patients With Myelodysplastic Syndrome
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... completed the sale to Galderma of all rights to ... by Valeant for $1.4 billion in cash, pursuant to ... completed its acquisition of Galderma. "We ... to a company that is firmly committed to the ...
(Date:7/10/2014)... 2014 CVS Caremark Corporation (NYSE: CVS ... a quarterly dividend of $0.275 (27.5 cents) per share on ... 1, 2014, to holders of record on July 21, 2014. ... is dedicated to helping people on their path to better ... the United States . Through the company,s more than ...
(Date:1/15/2014)... SAN ANTONIO , Jan. 15, 2014 Most ... take, according to a recent online survey* sponsored by ... among the National Osteoporosis Foundation online support community, ... to take medication that comes in a form other ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3
... Inc. (OTCBB: PLCSF), a company focused on innovative medical ... REMEDIAL II investigator-sponsored clinical trial of RenalGuard® ... , a peer-reviewed journal of the American Heart Association ... in the September 2011 issue of the publication.  The ...
... A national analysis conducted by Sperling,s BestPlaces and ... Columbus, Ohio, as one of the nation,s Hypertension ... factors and complications. The identification of the Hypertension ... hypertension awareness program called Commit to Control ...
Cached Medicine Technology:REMEDIAL II Trial of PLC's RenalGuard® Article Published in Circulation 2REMEDIAL II Trial of PLC's RenalGuard® Article Published in Circulation 3REMEDIAL II Trial of PLC's RenalGuard® Article Published in Circulation 4Columbus Included in Analysis of Top Hypertension Hot Spots in the United States 2Columbus Included in Analysis of Top Hypertension Hot Spots in the United States 3Columbus Included in Analysis of Top Hypertension Hot Spots in the United States 4
(Date:7/14/2014)... 14, 2014 Sometimes, thinking “inside the ... Playground announces its first product release, Joyboxx™ - The ... system. , Inventor and CEO, Deborah Semer ... have a storage solution for their ‘toys’ after she ... adult retail industry. , Semer met 30-year industry veteran ...
(Date:7/14/2014)... July 14, 2014 The Cabin Chiang ... its new Alumni Community website – a ... to help them maintain lifelong recovery wherever they live ... providing clients the tools to help them maintain their ... essential part of any reputable treatment programme. As a ...
(Date:7/14/2014)... (PRWEB) July 14, 2014 AttorneyOne.com, a ... all the latest information from the FDA on ... The FDA informed on July 11, that one lot ... mL, Flexible Container, by Hospira Inc., is recalled due ... parenteral replacement of extracellular losses of fluid and electrolytes, ...
(Date:7/14/2014)... According to the Blood Pressure Solution book review recently updated ... series of new information on high blood pressure . ... help readers understand more about blood pressure. The book shows ... to control hypertension naturally. , Blood Pressure ... by Ken Burge, a medical researcher and health consultant. Since ...
(Date:7/14/2014)... to the Boost Your Bust book review recently updated by Vkool.com, ... how to increase the size of their breasts naturally without medication ... , Chapter 1 – What Are Your Breasts And ... Natural Breast Enlargement Works , Chapter 3 – The ... 4 – The Groundwork , Chapter 5 – Personal ...
Breaking Medicine News(10 mins):Health News:Passionate Playground launches Joyboxx 2Health News:Passionate Playground launches Joyboxx 3Health News:The Cabin Chiang Mai Addiction Rehab Launches Industry-leading Aftercare Service 2Health News:The Cabin Chiang Mai Addiction Rehab Launches Industry-leading Aftercare Service 3Health News:Hospira Lactated Ringer’s and 5% Dextrose Injection Recalled: AttorneyOne Monitor and Keep Consumers Informed 2Health News:Hospira Lactated Ringer’s and 5% Dextrose Injection Recalled: AttorneyOne Monitor and Keep Consumers Informed 3Health News:Blood Pressure Solution Book Review Exposes Ken Burge's Hypertension Treatment Guide – Vkool.com 2Health News:Blood Pressure Solution Book Review Exposes Ken Burge's Hypertension Treatment Guide – Vkool.com 3Health News:Boost Your Bust Book Review Exposes Jenny Bolton's Breast Enhancement Guide – Vkool.com 2Health News:Boost Your Bust Book Review Exposes Jenny Bolton's Breast Enhancement Guide – Vkool.com 3
... research published in The Lancet states that, consuming a ... faster information processing and memory in the older adults. ... reduced levels of folate, and elevated levels of amino ... restricts cognitive ability, increasing the risk of dementia. ...
... the NHS trust to cater to mental problems afflicting the ... a document enabled by Durham County Council's inquiry committee, recognized ... in Durham and Darlington. The report threw light on the ... problems across six primary care trust areas in the region. ...
... the sake of good health., Students of Pittsburgh’s Plum ... last 10 months; via cafeteria meals. This was announced Thursday. ... by-products such as hulls of oats, soybeans, peas and rice, ... school meals to cut down calories while preserving a favorable ...
... showed reasonable resistance to Tamiflu, an antiviral, in two Egyptians who ... the medical community. ,The report also states that the ... in 2005. The occurrence of this strain in Egypt reveals that ... Tamiflu by the birdflu virus has not changed the WHO stance ...
... for short-term relief of chronic back pain, but their ... by researchers at Yale School of Medicine, who also ... in 24 percent of cases. ,“Patients with ... medications are used despite the concerns clinicians have with ...
... molecule that is part of a complex signaling network ... periventricular heterotopia (PVH), a congenital brain malformation, Yale School ... often leads to a variety of neurological disorders such ... It has many environmental and genetic causes, but is ...
Cached Medicine News:Health News:Long-Term Narcotics Use for Back Pain May Be Ineffective and Lead to Abuse 2Health News:Missing Molecule Has Important Role in a Developmental Brain Abnormality 2
M2 cemented hip stem....
Porous foundation 480 series....
Cemented foundation 460 series....
Porous foundation 440 series....
Medicine Products: